source
- Roche reports updated eye drug data and FDA filing acceptance, targets July 2027 decisionRoche Genentech has presented new data from its eye disease trials, a year after a mixed Phase 3 readout, and noted that the FDA has accepted its filing for vamikibart with a decision slated for Ju…
- Aspen Neuroscience files for Nasdaq IPO to fund Parkinson’s cell therapy programAspen Neuroscience, founded in 2018, announced plans to list on Nasdaq, aiming to raise additional capital for its Parkinson’s disease cell therapy program. The company's lead candidate, sasinepro…